<?xml version='1.0' encoding='utf-8'?>
<document id="27435752"><sentence text="Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6."><entity charOffset="88-97" id="DDI-PubMed.27435752.s1.e0" text="Efavirenz" /></sentence><sentence text="In this study, we present efavirenz physiologically based pharmacokinetic (PBPK) model development as an example of our best practice approach that uses a stepwise approach to verify the different components of the model"><entity charOffset="26-35" id="DDI-PubMed.27435752.s2.e0" text="efavirenz" /></sentence><sentence text=" First, a PBPK model for efavirenz incorporating in vitro and clinical pharmacokinetic (PK) data was developed to predict exposure following multiple dosing (600 mg q"><entity charOffset="25-34" id="DDI-PubMed.27435752.s3.e0" text="efavirenz" /></sentence><sentence text="d" /><sentence text=")" /><sentence text=" Alfentanil i"><entity charOffset="1-11" id="DDI-PubMed.27435752.s6.e0" text="Alfentanil" /></sentence><sentence text="v" /><sentence text=" and p" /><sentence text="o" /><sentence text=" drug-drug interaction (DDI) studies were utilized to evaluate and refine the CYP3A4 induction component in the liver and gut" /><sentence text=" Next, independent DDI studies with substrates of CYP3A4 (maraviroc, atazanavir, and clarithromycin) and CYP2B6 (bupropion) verified the induction components of the model (area under the curve [AUC] ratios within 1"><entity charOffset="58-67" id="DDI-PubMed.27435752.s11.e0" text="maraviroc" /><entity charOffset="69-79" id="DDI-PubMed.27435752.s11.e1" text="atazanavir" /><entity charOffset="85-99" id="DDI-PubMed.27435752.s11.e2" text="clarithromycin" /><entity charOffset="105-111" id="DDI-PubMed.27435752.s11.e3" text="CYP2B6" /><entity charOffset="113-122" id="DDI-PubMed.27435752.s11.e4" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e0" e2="DDI-PubMed.27435752.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e0" e2="DDI-PubMed.27435752.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e0" e2="DDI-PubMed.27435752.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e0" e2="DDI-PubMed.27435752.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e0" e2="DDI-PubMed.27435752.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e1" e2="DDI-PubMed.27435752.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e1" e2="DDI-PubMed.27435752.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e1" e2="DDI-PubMed.27435752.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e1" e2="DDI-PubMed.27435752.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e2" e2="DDI-PubMed.27435752.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e2" e2="DDI-PubMed.27435752.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e2" e2="DDI-PubMed.27435752.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e3" e2="DDI-PubMed.27435752.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27435752.s11.e3" e2="DDI-PubMed.27435752.s11.e4" /></sentence><sentence text="0-1" /><sentence text="7-fold of observed)" /><sentence text=" Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1" /><sentence text="7 vs" /><sentence text=" 1" /><sentence text="7 observed)" /><sentence text=" This validated mechanistic model can now be applied in clinical pharmacology studies to prospectively assess both the victim and perpetrator DDI potential of efavirenz"><entity charOffset="159-168" id="DDI-PubMed.27435752.s18.e0" text="efavirenz" /></sentence><sentence text="" /></document>